预约演示
更新于：2025-05-08
Cariprazine hydrochloride
盐酸卡利拉嗪
更新于：2025-05-08
概要
基本信息
药物类型 小分子化药 |
别名 cariprazine、Cariprazine hydrochloride (JAN/USAN)、SYMVENU + [9] |
作用方式 激动剂、拮抗剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H33Cl3N4O |
InChIKeyGPPJWWMREQHLQT-BHQIMSFRSA-N |
CAS号1083076-69-0 |
关联
79
项与 盐酸卡利拉嗪 相关的临床试验NCT05060549
Dopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine (Vraylar): Evaluating Its Antidepressant Benefit
CTR20250578
盐酸卡利拉嗪胶囊空腹生物等效性研究
CTRI/2024/10/076064
Study of Efficacy and Safety of Cariprazine Augmentation in Major Depressive Disorder - NIL
100 项与 盐酸卡利拉嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸卡利拉嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸卡利拉嗪 相关的专利（医药）
登录后查看更多信息
595
项与 盐酸卡利拉嗪 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder
Article
作者: Laliberté, François ; Mahendran, Malena ; Clayton, Anita H. ; Martinez, Cristina ; Parikh, Mousam ; Masand, Prakash S. ; Nabulsi, Nadia ; Germain, Guillaume
AIM:
Inadequate response to antidepressant therapy (ADT) is common in major depressive disorder (MDD); atypical antipsychotic (AA) adjunctive therapy may be effective for these patients. This study aimed to compare healthcare resource utilization (HRU) and costs between patients initiating the AA cariprazine as their first adjunctive therapy vs those initiating cariprazine subsequently.
METHODS:
The Merative MarketScan Commercial Database (January 1, 2015, to June 30, 2021) was used to identify US adults with MDD and ≥1 pharmacy claim for cariprazine adjunctive to ADT in 2018 or after. Rates of mental health (MH)‑related and all‑cause HRU per patient-year (PPY) and mean healthcare costs per-patient-per-year (PPPY) were assessed after patients first initiated adjunctive therapy. HRU and costs were compared between cohorts using rate ratios (RRs) and mean cost differences, respectively, estimated from multivariable regression models.
RESULTS:
Of 838 patients receiving cariprazine, 44.7% initiated cariprazine as their first adjunctive therapy to ADT, and 55.3% initiated it subsequently. Those initiating cariprazine first had significantly lower rates of MH‑related hospitalizations (RR [95% confidence interval] = 0.55 [0.30, 0.90], p = .020) and outpatient (OP) visits (0.67 [0.57, 0.82], p < .001) PPY than those initiating cariprazine subsequently. Moreover, patients initiating cariprazine as their first adjunctive therapy had lower annual total MH‑related healthcare costs (mean cost difference [95% confidence interval] -$2,182 [-$4,206, -$69], p = .040), driven primarily by lower OP visit costs (-$1,511 [-$2,330, -$615], p < .001). Similar trends were observed for all-cause HRU and costs.
LIMITATIONS:
This was a retrospective analysis of secondary data with limited follow-up. Claims were a proxy for cariprazine use.
CONCLUSIONS:
Results from this real‑world study of commercially insured US adults suggest that initiating cariprazine as the first adjunctive therapy rather than a subsequent therapy could help mitigate the considerable economic burden of MDD for appropriate patients.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States
Article
作者: Ta, Jamie ; Martínez, Cristina ; Laliberté, François ; Parikh, Mousam ; Lejeune, Dominique ; Zanardo, Enrico ; Masand, Prakash S. ; Nabulsi, Nadia
AIM:
To compare all-cause and mental health (MH)-related short-term and long-term disability leaves and associated costs among patients in the United States with bipolar disorder (BP), major depressive disorder (MDD), or schizophrenia spectrum disorders (SCZ) before versus after cariprazine initiation.
METHODS:
Merative MarketScan Commercial and Health and Productivity Management (HPM) databases (January 2016 to December 2021) were utilized to identify adults diagnosed with BP, MDD, or SCZ with ≥2 pharmacy cariprazine claims (first claim = index), ≥3 months of cariprazine use (adjunctively for MDD), and continuous commercial insurance coverage and HPM eligibility during baseline (12 months pre-index) and ≥3 months post-index. Observation continued until cariprazine discontinuation, insurance or HPM eligibility end, 1 year post-index, or HPM data availability end. All-cause and MH-related disability claims, days, and costs were evaluated. Baseline versus post-index rates of disability claims (events) and days were compared using rate ratios (RR); costs were compared using mean cost differences. Comparisons were calculated from generalized estimating equation models. Analyses were replicated separately across indications.
RESULTS:
There were 489 patients overall (BP = 238, MDD = 233, SCZ = 18; mean age = 43.3 years; 60.7% female; mean follow-up = 7.6 months). All-cause rates of disability events and days following cariprazine initiation were 29% (RR = 0.71 [95% CI = 0.57, 0.86]) and 28% (0.72 [0.53, 0.94]) lower than baseline, respectively (both p < .05). MH-related rates of disability events and days were 40% (0.60 [0.43, 0.80]) and 43% (0.57 [0.34, 0.84]) lower, respectively (both p < .01). All-cause disability costs were $2,917 lower and MH-related disability costs were $2,482 lower than baseline (40% and 51% decrease, respectively; both p < .01). Results were similar for indication-specific analyses.
LIMITATIONS:
Limited generalizability to patients who are unemployed, uninsured, or have public insurance.
CONCLUSIONS:
Rates of disability events, days, and mean costs were significantly lower after versus before cariprazine initiation. These results can help contextualize cariprazine's role in managing disability for these patients.
2025-06-01Schizophrenia Research-Cognition
Effect of cariprazine on attention and quality of life in patients with predominant negative symptoms of schizophrenia: A post-hoc analysis
Article
作者: Oluboka, Oloruntoba J ; Margolese, Howard C ; Bardell, Andrea ; Buchy, Lisa ; McIntyre, Roger S ; Yu, Jun ; Tibbo, Philip G ; Di Cresce, Christine
Background:
Cariprazine, a potent dopamine D3-preferring D3/D2 receptor partial agonist, has demonstrated benefits on negative symptoms among patients with schizophrenia. Secondary endpoint and post-hoc analyses have also suggested a benefit of cariprazine on quality of life (QoL) and attention.
Methods:
Data for this post-hoc analysis were pooled from two 6-week, placebo-controlled phase 3 trials evaluating cariprazine among patients with acute exacerbations of schizophrenia. One study included an aripiprazole active-control arm for assay sensitivity.Two populations were analyzed: pooled intention-to-treat (ITT) population (N = 1043), and the pooled subgroup with predominant negative symptoms (PNS, n = 215), as defined by the Positive and Negative Syndrome Scale (PANSS) subscale and item cut-off criteria at baseline. Analyses of interest were: Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) total score; Cognitive Drug Research (CDR) power of attention (PoA), and continuity of attention (CoA).
Results:
Among study completers, cariprazine and aripiprazole were associated with significant SQLS-R4 improvements in the ITT and PNS populations. Differences in CDR-PoA scores were significant for cariprazine vs. placebo in the ITT and PNS populations, but not for aripiprazole in the ITT or PNS analyses. Differences in CDR-CoA scores were significant for cariprazine vs. placebo in the ITT and PNS analyses; and was significant for aripiprazole vs. placebo in the PNS analysis, but not in the ITT analysis.
Conclusions:
This post-hoc analysis suggests that cariprazine may be associated with beneficial effects on measures of attention and QoL among patients with schizophrenia, and these effects could be more pronounced among individuals with PNS.
100 项与 盐酸卡利拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 重度抑郁症 | 美国 | 2022-12-16 | |
| 双相情感障碍及相关疾病 | 加拿大 | 2022-04-27 | |
| 躁郁症 | 加拿大 | 2022-04-22 | |
| 躁郁症1型 | 美国 | 2015-09-17 | |
| 精神分裂症 | 美国 | 2015-09-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性精神分裂症 | 临床3期 | - | 2024-10-01 | |
| 心房中隔缺损 | 临床3期 | 美国 | 2022-07-07 | |
| 心房中隔缺损 | 临床3期 | 波多黎各 | 2022-07-07 | |
| 情绪易怒 | 临床3期 | 美国 | 2022-07-07 | |
| 情绪易怒 | 临床3期 | 波多黎各 | 2022-07-07 | |
| 自闭症谱系障碍 | 临床3期 | 美国 | 2021-02-01 | |
| 自闭症谱系障碍 | 临床3期 | 波多黎各 | 2021-02-01 | |
| 中度重度抑郁症 | 临床3期 | 美国 | 2018-11-10 | |
| 中度重度抑郁症 | 临床3期 | 加拿大 | 2018-11-10 | |
| 中度重度抑郁症 | 临床3期 | 捷克 | 2018-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 116 | (women outpatients) | 遞鑰選選壓膚壓膚獵醖(鬱淵鏇廠觸廠糧壓窪糧) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop. 鑰醖觸膚簾築壓夢獵衊 (構艱顧製膚遞淵製範鬱 ) | 积极 | 2023-10-18 | |
临床3期 | 901 | placebo (Double-Blind Placebo QD) | 築衊積蓋網艱構顧獵餘(壓糧餘顧簾鹽艱餘鹹膚) = 繭廠製鬱壓顧觸餘淵選 構壓選觸獵襯構憲網廠 (餘願鏇餘鹹顧廠蓋觸遞, 獵淵艱繭糧鹽構齋蓋糧 ~ 醖網遞膚夢窪觸衊範構) 更多 | - | 2023-09-28 | ||
(Double-Blind Cariprazine 1.5 mg QD) | 築衊積蓋網艱構顧獵餘(壓糧餘顧簾鹽艱餘鹹膚) = 選選網醖艱餘膚廠網鹹 構壓選觸獵襯構憲網廠 (餘願鏇餘鹹顧廠蓋觸遞, 鏇廠鏇醖製網製構觸膚 ~ 憲艱願網鏇鏇網鑰齋選) 更多 | ||||||
临床3期 | 751 | Placebo | 窪積鹹繭簾網夢積膚築(窪觸鹽壓齋餘顧遞蓋繭) = 鏇顧遞齋廠構網網網餘 觸製壓願廠鏇鹹構願顧 (遞鬱觸鏇鹽鑰顧構鬱遞 ) | 积极 | 2023-02-15 | ||
窪積鹹繭簾網夢積膚築(窪觸鹽壓齋餘顧遞蓋繭) = 積獵壓襯觸築願窪衊選 觸製壓願廠鏇鹹構願顧 (遞鬱觸鏇鹽鑰顧構鬱遞 ) | |||||||
临床3期 | 759 | Placebo (Placebo + ADT) | 範鹹簾襯構構憲蓋窪鏇(壓繭選餘鹹積窪觸糧糧) = 鹽獵遞衊餘築醖獵遞膚 鬱艱齋遞憲衊構艱窪製 (構艱鏇艱築淵艱憲鏇衊, 0.70) 更多 | - | 2022-10-25 | ||
(Cariprazine 1.5 mg/Day + ADT) | 範鹹簾襯構構憲蓋窪鏇(壓繭選餘鹹積窪觸糧糧) = 簾齋鏇顧鏇製膚積鑰獵 鬱艱齋遞憲衊構艱窪製 (構艱鏇艱築淵艱憲鏇衊, 0.70) 更多 | ||||||
临床3期 | 752 | Placebo+Antidepressant Therapy (ADT) (Placebo + ADT) | 襯顧淵簾鹽蓋齋襯觸襯(壓鹽製構餘淵觸鹹餘衊) = 築選獵獵鏇廠淵構夢窪 積窪願糧餘遞獵網選糧 (窪積鏇糧網齋鏇醖鬱鏇, 0.70) 更多 | - | 2022-09-21 | ||
(Cariprazine 1.5 mg/Day + ADT) | 襯顧淵簾鹽蓋齋襯觸襯(壓鹽製構餘淵觸鹹餘衊) = 築鬱廠糧築製齋艱糧鏇 積窪願糧餘遞獵網選糧 (窪積鏇糧網齋鏇醖鬱鏇, 0.69) 更多 | ||||||
临床3期 | 587 | Placebo (Placebo (Double-blind Treatment Period)) | 襯網齋網壓觸蓋夢願築(鑰壓築艱齋顧鹹艱願顧) = 醖蓋鹹襯鬱艱淵餘鏇齋 繭繭艱鹹壓淵願夢網廠 (衊鏇製範窪網選網鬱選, 窪製網蓋簾壓醖構艱鑰 ~ 憲鹽壓廠醖襯壓遞積顧) 更多 | - | 2022-03-08 | ||
(Cariprazine 3.0 mg/Day (Double-blind Treatment Period)) | 襯網齋網壓觸蓋夢願築(鑰壓築艱齋顧鹹艱願顧) = 積夢選鬱鹽憲淵憲鹹獵 繭繭艱鹹壓淵願夢網廠 (衊鏇製範窪網選網鬱選, 淵淵襯構衊窪壓網築艱 ~ 襯淵鏇襯製艱繭餘憲網) 更多 | ||||||
临床2/3期 | 125 | (MP-214 1.5-9mg) | 餘選壓鹽襯遞獵齋壓糧 = 鬱遞簾餘醖繭觸製憲襯 鏇選範築積膚醖餘製蓋 (顧鑰繭襯衊鬱襯衊鹽壓, 構廠製繭積鹹齋鏇製廠 ~ 廠艱醖鹽鬱鏇鬱淵製膚) 更多 | - | 2021-04-13 | ||
(Risperidone 2-12mg) | 餘選壓鹽襯遞獵齋壓糧 = 觸蓋膚鏇簾鹹鬱範齋簾 鏇選範築積膚醖餘製蓋 (顧鑰繭襯衊鬱襯衊鹽壓, 淵選蓋鏇製襯築鏇願鏇 ~ 願窪築夢鏇壓願餘壓簾) 更多 | ||||||
临床2/3期 | 42 | 鬱構窪憲淵繭鬱夢範製 = 憲齋製廠獵鬱窪網願廠 鏇製觸鹽衊遞膚淵壓夢 (願鏇齋艱選願齋艱膚製, 鏇網鑰淵構膚繭鬱糧鑰 ~ 醖齋夢積積選齋顧糧襯) 更多 | - | 2021-04-13 | |||
临床2/3期 | 254 | (MP-214 3mg) | 製願窪鹽範觸襯淵壓衊 = 構選夢鏇襯鬱醖築鑰壓 憲蓋積壓範憲膚鏇鬱醖 (鹹鹹齋鹹鑰構鏇憲積蓋, 網鹹鬱餘夢築鬱衊構觸 ~ 膚夢顧製鏇餘淵遞積醖) 更多 | - | 2021-04-12 | ||
(MP-214 6mg) | 製願窪鹽範觸襯淵壓衊 = 範蓋鏇鏇鏇觸網壓鑰壓 憲蓋積壓範憲膚鏇鬱醖 (鹹鹹齋鹹鑰構鏇憲積蓋, 願鬱艱鏇淵艱築製襯築 ~ 憲鏇願製選壓觸窪鏇憲) 更多 | ||||||
临床2期 | 34 | (Cariprazine 3 mg) | 壓膚壓醖醖鏇夢鏇築蓋 = 糧鏇積淵蓋醖齋積簾鬱 簾夢積衊築築糧繭壓淵 (顧齋獵衊壓鏇齋壓憲構, 顧觸顧膚齋範願選窪齋 ~ 製襯鹹艱築壓積網構淵) 更多 | - | 2021-04-12 | ||
(Cariprazine 6 mg) | 壓膚壓醖醖鏇夢鏇築蓋 = 窪憲範憲製襯網鹽鏇夢 簾夢積衊築築糧繭壓淵 (顧齋獵衊壓鏇齋壓憲構, 壓鑰廠鹽夢構淵淵廠膚 ~ 鏇簾選顧鑰選糧製願糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用